469 related articles for article (PubMed ID: 2644532)
1. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors.
Fisher B; Costantino J; Redmond C; Poisson R; Bowman D; Couture J; Dimitrov NV; Wolmark N; Wickerham DL; Fisher ER
N Engl J Med; 1989 Feb; 320(8):479-84. PubMed ID: 2644532
[TBL] [Abstract][Full Text] [Related]
2. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors.
Fisher B; Redmond C; Dimitrov NV; Bowman D; Legault-Poisson S; Wickerham DL; Wolmark N; Fisher ER; Margolese R; Sutherland C
N Engl J Med; 1989 Feb; 320(8):473-8. PubMed ID: 2644531
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen versus placebo: double-blind adjuvant trial in elderly women with stage II breast cancer.
Cummings FJ; Gray R; Davis TE; Tormey DC; Harris JE; Falkson GG; Arseneau J
NCI Monogr; 1986; (1):119-23. PubMed ID: 3534584
[TBL] [Abstract][Full Text] [Related]
4. Systemic therapy in node-negative patients: updated findings from NSABP clinical trials. National Surgical Adjuvant Breast and Bowel Project.
Fisher B; Redmond C
J Natl Cancer Inst Monogr; 1992; (11):105-16. PubMed ID: 1627417
[TBL] [Abstract][Full Text] [Related]
5. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer.
Fyles AW; McCready DR; Manchul LA; Trudeau ME; Merante P; Pintilie M; Weir LM; Olivotto IA
N Engl J Med; 2004 Sep; 351(10):963-70. PubMed ID: 15342804
[TBL] [Abstract][Full Text] [Related]
6. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
[TBL] [Abstract][Full Text] [Related]
7. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer.
Fisher B; Redmond C; Poisson R; Margolese R; Wolmark N; Wickerham L; Fisher E; Deutsch M; Caplan R; Pilch Y
N Engl J Med; 1989 Mar; 320(13):822-8. PubMed ID: 2927449
[TBL] [Abstract][Full Text] [Related]
8. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
Goss PE
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S8-12. PubMed ID: 16730271
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study.
Mansour EG; Gray R; Shatila AH; Osborne CK; Tormey DC; Gilchrist KW; Cooper MR; Falkson G
N Engl J Med; 1989 Feb; 320(8):485-90. PubMed ID: 2915651
[TBL] [Abstract][Full Text] [Related]
10. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
[TBL] [Abstract][Full Text] [Related]
11. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
[TBL] [Abstract][Full Text] [Related]
12. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.
Forbes JF
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S2-7. PubMed ID: 16730270
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
[TBL] [Abstract][Full Text] [Related]
14. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
15. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD
J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417
[TBL] [Abstract][Full Text] [Related]
16. Sites of failure in breast cancer patients with extracapsular invasion of axillary lymph node metastases. No need for axillary irradiation?!
Gruber G; Menzi S; Forster A; Berclaz G; Altermatt HJ; Greiner RH
Strahlenther Onkol; 2005 Sep; 181(9):574-9. PubMed ID: 16170484
[TBL] [Abstract][Full Text] [Related]
17. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Hillner BE
Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
[TBL] [Abstract][Full Text] [Related]
18. Treatment of primary breast cancer with chemotherapy and tamoxifen.
Fisher B; Redmond C; Brown A; Wolmark N; Wittliff J; Fisher ER; Plotkin D; Bowman D; Sachs S; Wolter J; Frelick R; Desser R; LiCalzi N; Geggie P; Campbell T; Elias EG; Prager D; Koontz P; Volk H; Dimitrov N; Gardner B; Lerner H; Shibata H
N Engl J Med; 1981 Jul; 305(1):1-6. PubMed ID: 7015139
[TBL] [Abstract][Full Text] [Related]
19. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
20. Negative margin status improves local control in conservatively managed breast cancer patients.
Obedian E; Haffty BG
Cancer J Sci Am; 2000; 6(1):28-33. PubMed ID: 10696736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
